Kimberly Lynn Blackwell, MD

Adjunct Professor in the Department of Medicine
Assistant Professor in Radiation Oncology
Member of the Duke Cancer Institute
Campus mail Duke Box 3893, Durham, NC 27710
Phone (919) 668-1748
Email address black034@mc.duke.edu

Breast cancer angiogenesis
Breast cancer in younger women
Hormonal therapy
Neoadjurant therapy for breast cancer

Current Clinical Investigations

Principal Investigator, A Phase I-II Study of Neoadjuvant Evacet/Paclitaxel/Hyperthermia in Locally Advanced Breast Cancer Patients.

Investigator, Development of Screening Markers for Breast Cancer using Circulating Immune Complexes: Collaborative Study with Diagen Medical Technologies.

Principal Investigator, Use of Plasma D-Dimer as a Predictive Marker in Colorectal Carcinoma: Correlative Science Study with Genentech, Inc.

Principal Investigator, A randomized, Phase II study of gabapentin or glutamine to prevent the peripheral neuropathy/myalgia associated with weekly taxol administration in metastatic breast and lung cancer.

Investigator, A Phase 2, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the treatment of Metastatic Breast Cancer in Postmenopausal Women who have failed Tamoxifen therapy. Genetics Institute.

Investigator, A Phase I Study of Combined Doxil/Hyperthermia in Stage IV Breast Cancer.

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1997 - 2000
  • Medical Resident, Medicine, Duke University, 1994 - 1997
  • M.D., Mayo School of Health Sciences, 1994

Publications

Force, J, Howie, LJ, Abbott, SE, Bentley, R, Marcom, PK, Kimmick, G, Westbrook, K, Sammons, SL, Parks, M, Topping, DL, Emerson, R, Broadwater, G, Hyslop, T, Blackwell, KL, and Nair, SK. "Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype." Clinical Breast Cancer 18, no. 5 (October 2018): 410-417.

PMID
29615305
Full Text

Sammons, S, Kornblum, NS, and Blackwell, KL. "Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer." Targeted Oncology (August 22, 2018).

PMID
30136059
Full Text

Hortobagyi, GN, Stemmer, SM, Burris, HA, Yap, YS, Sonke, GS, Paluch-Shimon, S, Campone, M, Petrakova, K, Blackwell, KL, Winer, EP, Janni, W, Verma, S, Conte, P, Arteaga, CL, Cameron, DA, Mondal, S, Su, F, Miller, M, Elmeliegy, M, Germa, C, and O'Shaughnessy, J. "Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer." Annals of Oncology : Official Journal of the European Society for Medical Oncology 29, no. 7 (July 2018): 1541-1547.

PMID
29718092
Full Text

Argento, AC, Gilstrap, DL, Shofer, S, Mahmood, K, Blackwell, K, and Wahidi, MM. "Endobronchial Ultrasound-guided Transbronchial Needle Aspiration in the Diagnosis of Breast Cancer Thoracic Metastases and Detection of Receptor Discordance." Journal of Bronchology & Interventional Pulmonology 25, no. 3 (July 2018): 176-180.

PMID
29944588
Full Text

Bardia, A, Gucalp, A, DaCosta, N, Gabrail, N, Danso, M, Ali, H, Blackwell, KL, Carey, LA, Eisner, JR, Baskin-Bey, ES, and Traina, TA. "Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer." Breast Cancer Research and Treatment (May 9, 2018).

PMID
29744674
Full Text

Blackwell, K, Gligorov, J, Jacobs, I, and Twelves, C. "The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer." Clinical Breast Cancer 18, no. 2 (April 1, 2018): 95-113. (Review)

Full Text

Harbeck, N, Gascón, P, Krendyukov, A, Hoebel, N, Gattu, S, and Blackwell, K. "Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies (Accepted)." Oncologist (January 1, 2018).

Full Text

Blackwell, K, Gascon, P, Krendyukov, A, Gattu, S, Li, Y, and Harbeck, N. "Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy." Annals of oncology : official journal of the European Society for Medical Oncology 29, no. 1 (January 2018): 244-249.

PMID
29091995
Full Text

Shammas, RL, Cho, EH, Glener, AD, Poveromo, LP, Mundy, LR, Greenup, RA, Blackwell, KL, and Hollenbeck, ST. "Association Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis." Journal of the American College of Surgeons 225, no. 6 (December 2017): 731-739.e1.

PMID
28985927
Full Text

Narloch, JL, Farber, SH, Sammons, S, McSherry, F, Herndon, JE, Hoang, JK, Yin, F-F, Sampson, JH, Fecci, PE, Blackwell, KL, Kirkpatrick, JP, and Kim, GJ. "Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis." Neuro Oncology 19, no. 10 (October 2017): 1391-1397.

PMID
28472527
Full Text

Pages